It is made available under a CC-BY-NC-ND 4.0 International license .

1 Original Article

2 **Title**

- 3 Adherence to methotrexate and associated factors considering social desirability in patients
- 4 with rheumatoid arthritis: a multicenter cross-sectional study
- 5

6 Authors

- 7 Nobuyuki Yajima, MD, MPH, PhD^{1,2,3}; Takashi Kawaguchi, PhD⁴; Ryo Takahashi, MD¹;
- 8 Hiroki Nishiwaki, MD, MPH, PhD ^{5,6}; Yoichi Toyoshima, MD, PhD (ORCID ID,

9 0000-0002-6097-2552)⁷; Koei Oh, MD, PhD⁸; Tsuyoshi Odai, MD, PhD^{9.10}; Takayuki Kanai,

- 10 MD, PhD¹¹; Donald E. Morisky, ScD, MSPH¹²; Takuhiro Yamaguchi, PhD¹³; Tsuyoshi
- 11 Kasama, MD, PhD (ORCID ID, 0000-0002-3871-6456)¹

12 Affiliations

- ¹³ ¹ Division of Rheumatology, Department of Medicine, Showa University School of Medicine,
- 14 Tokyo, Japan
- ¹⁵ ² Department of Healthcare Epidemiology, Kyoto University Graduate School of Medicine
- 16 and Public Health, Kyoto, Japan
- 17 ³ Center for Innovative Research for Communities and Clinical Excellence, Fukushima

- 18 Medical University, Fukushima, Japan
- ⁴ Department of Practical Pharmacy, School of Pharmacy, Tokyo University of Pharmacy
- 20 and Life Sciences, Tokyo, Japan
- ⁵ Division of Nephrology, Department of Internal Medicine, Showa University Fujigaoka
- 22 Hospital, Yokohama, Japan
- ⁶ Showa University Research Administration Center, Tokyo, Japan
- ²⁴ ⁷ Department of Orthopedic Surgery, Showa University Toyosu Hospital, Tokyo, Japan
- 25 ⁸ Department of Orthopedic Surgery, Showa University Northern Yokohama Hospital,
- 26 Yokohama, Japan
- 27 ⁹ Department of Internal Medicine, Showa University Northern Yokohama Hospital,
- 28 Yokohama, Japan
- ²⁹ ¹⁰ Department of Rheumatology, Yokohama Asahi Central General Hospital, Kanagawa,
- 30 Japan.
- ³¹ ¹¹ Department of Nephrology, Kanto Rosai Hospital, Kawasaki, Japan
- ³² ¹² Department of Community Health Sciences, UCLA Fielding School of Public Health, Los
- 33 Angeles, United States
- ¹³ Division of Biostatistics, Tohoku University Graduate School of Medicine, Miyagi, Japan

It is made available under a CC-BY-NC-ND 4.0 International license .

35 **Corresponding author:**

- 36 Nobuyuki Yajima
- 37 Division of Rheumatology, Department of Medicine, Showa University School of Medicine,
- 38 Tokyo, Japan
- 39 Address:1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan
- 40 Phone: +81-3-3784-8942; Fax:+81-3-3784-8946
- 41 E-mail: n. yajima@med. showa-u. ac. jp
- 42 ORCID iD: 0000-0002-8292-3962
- 43
- 44 Abstract

Background: Assessing medication adherence in rheumatoid arthritis (RA) is clinically significant as low adherence is associated with high disease activity. Self-reported medication adherence surveys have been shown to have problems with overestimation of adherence due to social desirability bias. However, no MTX adherence studies adjusted for social desirability have been conducted to date. This study aimed to evaluate adherence to MTX and perform an investigatory search for factors associated with MTX adherence including social desirability.

52	Methods: This cross-sectional multicenter study was conducted among adult RA patients
53	consuming oral MTX for \geq 3 months. We examined the distribution of MTX adherence,
54	according to the eight-item Morisky Medication Adherence Scale (MMAS-8). Social
55	desirability was using the Social Desirability Scale (SDS). Furthermore, an exploratory factor
56	analysis involving social desirability was examined to identify factors associated with MTX
57	adherence using linear regression analysis. To deal with missing values, we used multiple
58	imputations with chained equations methods.
59	Results: A total of 165 RA patients were enrolled. The median age was 64 years, and 86.1%
60	were women. Based on the MMAS-8, low, medium, and high adherences were noted in
61	12.1%, 60.0%, and 27.9% of participants, respectively. High social desirability (coefficient,
62	0.14; 95% confidence interval [CI], 0.05–0.23; p<0.05) and high age (coefficient per 10 years,
63	0.16; 95% CI, 0.01-0.03; p<0.05) were associated with high MTX adherence, whereas
64	full-time work was negatively associated with high MTX adherence (coefficient, -0.50; 95%
65	CI, -0.95–-0.05; p<0.05).
66	Conclusions: A large proportion of patients with RA do not take MTX as prescribed. High
67	social desirability, high educational level, and non-full-time work may be associated with
68	high MTX adherence. Physicians should confirm MTX adherence before switching or adding

It is made available under a CC-BY-NC-ND 4.0 International license .

- 69 disease-modifying anti-rheumatic drugs in cases of uncontrolled disease activity.
- 70 Keywords: rheumatoid arthritis, methotrexate, drug monitoring
- 71

```
72 Background
```

73 Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic 74 inflammation. RA affects the joints and leads to functional disability in the absence of 75 appropriate treatment [1]. The 2015 American College of Rheumatology (ACR) and the 2019 76 European League against Rheumatism recommendations suggested the early use of 77 disease-modifying antirheumatic-drugs (DMARDs), usually methotrexate (MTX), in most 78 active RA patients [2,3]. Several studies have reported that low medication adherence is 79 associated with high RA disease activity [4,5]. Hence, MTX adherence in RA patients is 80 crucial. 81 Non-adherence can be categorized as non-initiation, poor execution (accidental or 82 intentional) or non-persistence [6]. As a chronic disease, RA is important for drug

continuation, and attention should be focused on non-persistence non-adherence. Several
studies on adherence to MTX have been conducted. However, MTX adherence differed
among the studies because of the various definitions of adherence, different follow-up
durations, and heterogeneity of patient populations. A previous study reported that MTX

87	adherence is associated with age, sex, race, RA disease activity, patient beliefs about the
88	medication, disease duration, mental health, and socio-economic status (SES) [4,7-11]. In a
89	systematic review, beliefs on the necessity and efficacy of MTX, high mood, mild disease,
90	and MTX monotherapy were identified as the most reliable variables related to MTX
91	adherence [12].
92	The common propensity for people to show themselves in the most favorable light in
93	relation to society values and standards is known as social desirability [13]. Clinically, social
94	desirability may result in underreporting of socially and culturally "undesirable" habits and
95	behaviors, which may eventually result in lost chances for intervention and unrecognized
96	pharmacological contraindications [14,15]. It is well known to influence the use of
97	self-reported questionnaires in research. A previous study reported that social desirability is
98	the tendency to respond to self-reported items in a way that reflects better on the respondent
99	rather than acting accurately and truthfully [16]. Self-reported medication adherence surveys
100	have been shown to have problems with overestimation of adherence due to social
101	desirability bias [17,18]. A previous MTX adherence study has reported the need to control
102	this bias [19]; however, no studies have investigated the MTX adherence survey by
103	controlling for social desirability. Thus, this study aimed to evaluate the effect of already

It is made available under a CC-BY-NC-ND 4.0 International license .

- 104 known variables plus social desirability.
- 105 Methods
- 106 Study design
- 107 This cross-sectional study was conducted in four hospitals: Showa University Hospital,
- 108 Showa University Northern Yokohama Hospital, Showa University Fujigaoka Hospital, and
- 109 Kanto Rosai Hospital. Data collection was conducted only once during the survey.
- 110 **Patient population**
- 111 Participants were outpatients who met the 2010 ACR criteria for RA [20]. The inclusion
- 112 criteria were age ≥ 20 years and consumption of oral MTX for ≥ 3 months. The exclusion
- 113 criteria were patients with dementia, restlessness, and severe psychiatric disorders.
- 114 Consecutive sampling was employed. Patients were recruited between August 2013 and

115 October 2014.

116 Outcome

The primary outcome was the distribution of MTX adherence according to MMAS-8 at the time of the survey based on the patient's description. MMAS-8 consists of an eight-item questionnaire [21-23]. MMAS-8 scores range from 0 to 8 and are classified as follows: low, </br>
120 <6; medium, >6 and <8; and high, 8. Originally, MMAS-8 was developed for daily</td>

It is made available under a CC-BY-NC-ND 4.0 International license .

121	administration of oral medicine. MTX was administered once a week; thus, we developed the
122	Japanese questionnaire for MTX accordingly after obtaining the original developer's
123	permission. First, a physician (N.Y.), a pharmacist (T.K.) with experience in scale
124	development translated the scale into Japanese. Second, it was back-translated into English
125	by two professional translators. N.Y., T.K. and two professional translators compared the
126	items with the original items, and discussed the questionnaire and achieved a consensus, and
127	revised the translated and back-translated versions. Finally, we were sent to the original
128	author to confirm the semantic content, and some minor improvements were made. The final
129	version was approved by the original author. Then, five Japanese RA participants took part in
130	a pilot test to see if they could understand the questions and respond to them clearly, if the
131	language was clear, if there were any technical or strange words that the subjects couldn't
132	understand, and if the questions were appropriate for Japanese culture.
133	Data collection
134	Social desirability is typically assessed using the Social Desirability Scale (SDS) developed

by Crowne and Marlowe in 1960, with 33 items [24]. By "the urge to seek acceptance by

- 136 acting in a culturally relevant and acceptable way," this scale defines social desirability.
- 137 Furthermore, a 13-item SDS was developed with confirmed validity and reliability [25-27].

It is made available under a CC-BY-NC-ND 4.0 International license .

138	In this study, we used the 13-item SDS. The responses are recorded on "True" or "False. Add
139	1 point to the score for each "True" response to statements 5, 7, 9, 10, and 13. Add 0 points to
140	the score for each "False" response to these statements. Add 1 point to the score for each
141	"False" response to statements 1,2,3,4,6, 8, 11, and 12. Add 0 points to the score for each
142	"True" response to these statements. The score by domains ranges from 0 to 13. Higher
143	scores indicated higher social desirability.
144	MTX dose, MTX dosing frequency, duration of MTX treatment were collected. RA disease
145	activity was assessed using the Disease Activity Score in 28 joints (DAS28-ESR). [28].
146	Activities of daily living (ADL) was assessed using the modified Health Assessment
147	Questionnaire (mHAQ), which is a self-reported questionnaire that measures function,
148	including ADL performance. Depression state was defined using the Centre for
149	Epidemiological Studies-Depression (CES-D) scale-[29]. The patient's perceptions towards
150	medications were assessed using the Belief about Medicines Questionnaire-Specific
151	(BMQ-specific), which includes two domains, BMQ-Specific necessity (5 items) and
152	BMQ-Specific concern (5 items). We used the BMQ necessity-concern differential
153	("BMQ-Specific necessity" minus "BMQ-Specific concern") predicted adherence most
154	strongly in studies affecting adherence [30]. Pain severity was assessed using the Brief Pain

It is made available under a CC-BY-NC-ND 4.0 International license .

155Inventory (BPI).-We used the average numerical rating scale (NRS) pain score other clinical 156studies have applied in the multivariable analysis. Short Form-8 (SF-8) is a health-related 157 quality of life (QoL) questionnaire [31,32]- We used two summary scores: mental component 158summary (MCS; showing mental status) and physical component summary (PCS; showing 159physical status). The Japanese versions of mHAQ, CES-D, BMQ, BPI, SDS, and SF-8 were 160 validated [33, 34]. 161 Additionally, we obtained data on SES, including marital status, educational level, 162employment status, and living status. Data on patient characteristics, medication, and SES 163 were further collected using questionnaires. Other data were obtained from medical chart 164 records. After consulting the doctor, the participants answered the Morisky Medication 165 Adherence Scale (MMAS-8), mHAQ, CES-D, BMQ, BPI, SDS, SF-8, and SES 166 questionnaires; they returned the completed questionnaires to the data center by mail. 167 Statistical analyses 168 MMAS-8, sex, CES-D, and SES were used as categorical variables, whereas age, MTX 169 dose, MTX dosing frequency, duration of MTX treatment, disease duration, DAS28-ESR,

170 mHAQ, BMQ, BPI, SDS, and SF-8 were used as continuous variables. Summary statistics

171 were presented as median with interquartile range (IQR) and numbers with proportion (%).

172	First, we evaluated the distribution of MTX adherence according to MMAS-8. Subsequently,
173	we compared MMAS-8 and pre-described factors using one-way analysis of variance
174	(ANOVA), Kruskal-Wallis test, and chi-squared test. For significant factors, we conducted a
175	trend analysis. Finally, multiple linear regression analysis was performed to exploratively
176	assess factors associated with MTX adherence The co-variables selected were as follows: age,
177	sex, disease duration, RA disease activity (DAS28-ESR), depression state (CES-D),
178	reliability of the medication (BMQ necessity-concern differential), social desirability (SDS),
179	educational level (more than, equal to college-level, or not), and employment status (full-time
180	work or not). These factors were further selected based on previous studies and clinical
181	importance [4,7-11,35-37]. To compare the mean DAS-28 scores among the three groups
182	using ANOVA, the effect size (small, 0.1; medium, 0.25; and large: 0.4) customarily
183	proposed by Cohen [38] was set at medium (0.25), the significance level was set at 5% on
184	both sides, and the power was set at 80%. The total number of cases was calculated to be 159.
185	The target number of cases was 176, assuming a dropout rate of 10%.
186	To deal with missing values, we used multivariable multiple imputations with chained
187	equations methods to increase power and minimize selection bias since we considered
188	missing data to be an assumption of missing at random. We included age, sex, disease

189	duration, RA disease activity	, depression state	reliability of the	medication,	social desirability,
-----	-------------------------------	--------------------	--------------------	-------------	----------------------

190	educational level, and employment status for each imputation model. We generated 10
191	imputed datasets and combined coefficient estimates using Rubin's rules for each imputation.
192	A two-sided p-value <0.05 was considered statistically significant. All statistical analyses
193	were conducted using STATA 14.2 (StataCorp LP, College Station, TX) software.
194	Ethical considerations
195	The ethics committee of Showa University Hospital (approval number 1446) and Showa
196	University Toyosu Hospital, Showa University Northern Yokohama Hospital, Kanto Rosai
197	Hospital approved this study, and informed consent was obtained from all participants before
198	study enrolment. All study procedures were performed in accordance with the Declaration of
199	Helsinki. Patient information was anonymized and de-identified before analysis.
200	Results
201	Patient flow chart
202	Figure 1 shows the patient flow chart. Initially, 181 RA patients were invited. Of 169

- 203 patients eligible for the study, four were excluded because of missing MTX adherence data
- 204 (n=2) and clinical data (n=2). A total of 165 RA patients were included in the final analysis.
- 205 Baseline characteristics

It is made available under a CC-BY-NC-ND 4.0 International license .

- 206 The characteristics of the participants are shown in Table 1. The median age of the patients
- was 64 years (IQR, 54–72), and 86.1% were women. The median dose of MTX was 8 mg per
- week (IQR, 6–12), median MTX dosing frequency was three times per week (IQR, 2–3), and
- 209 median duration of MTX treatment was 36 months (IQR, 17–75). The proportion of missing
- 210 data varied from 0 to 15.2% (Supplementary table 1).

211 **INSERT TABLE 1 HERE**

212 Distribution of MTX adherence

Based on MMAS-8, low, medium, and high adherence rates were noted in 12% (20/165),

214 60% (99/165), and 28% (46/165) of cases, respectively. The median MMAS-8 score was 7

215 (IQR, 6.5–8).

216 Patient's characteristics by grade of MTX adherence

217 Patient's characteristics by grade of MTX adherence divided by MMAS-8 are shown in

Table 1. A significant correlation between levels of MTX adherence and age, mHAQ, SDS,

- 219 SF-8 (PCS), and employment status was found. Based on trend analysis, older participants
- 220 had significantly high adherence, and the higher the social desirability, the higher the
- adherence. However, a significant correlation between MTX adherence and mHAQ and SF-8
- 222 (PCS) was not observed in the trend analysis.

It is made available under a CC-BY-NC-ND 4.0 International license .

223 Factors associated with high MTX adherence considering social desirability

224	In the multiple linear regression analysis adjusted for age, sex, disease duration, RA disease
225	activity (DAS28-ESR), depression state (CES-D), reliability of the medication (BMQ
226	necessity-concern differential), social desirability (SDS), educational level (more than or
227	equal to college-level or not), and employment status (full-time work or not), higher social
228	desirability (coefficient, 0.14; 95% confidence interval [CI], 0.05-0.23; p<0.05) and higher
229	age (coefficient per 10 years, 0.16; 95% CI, 0.01-0.03; p<0.05) were associated with high
230	MTX adherence, whereas full-time work was negatively related to high MTX adherence
231	(coefficient, -0.50; 95% CI, -0.950.05; p<0.05) (Table 2).
232	INSERT TABLE 2 HERE
233	
234	Discussion
005	
235	Elderly participants and high social desirability were significantly associated with high
235 236	Elderly participants and high social desirability were significantly associated with high adherence based on trend analysis. Multiple linear regression analysis showed that high MTX
236	adherence based on trend analysis. Multiple linear regression analysis showed that high MTX

239 In our study, only 27.9% of the participants showed high medication adherence. Several

240	studies reported that adherence to DMARDS was 40%-107% [10,39,40]. There are several
241	potential reasons for the observed low adherence. First, the method of adherence
242	measurement in each study was different. There were interviews, questionnaires, tablet count,
243	drug concentration, and doctor's judgment as measurements. A previous study showed that
244	the adherence to interview, tablet count, drug concentration, and doctor's judgment were 96%,
245	77%, 58%, and 42%, respectively, which showed vast differences [41]. Since each
246	measurement has advantages and disadvantages, the gold standard is not determined. We
247	chose a self-reported questionnaire in this study since this scale is not expensive or invasive
248	and can be possibly validated. Second, the time point of adherence measurement was
249	different between the studies. We measured adherence during the maintenance period (mean
250	disease duration, 53 months). A previous report suggested that the adherence of DMARDs in
251	the early period was low (58%) [5]. Another study reported the adherence to
252	salazosulfapyridine as 87% at three years from the start of medication [36]. In contrast, the
253	adherence to DMARDs in the maintenance period varied from 84%, ⁴ 70% [42], to 95.4%
254	[43]. Previous reports have suggested that the adherence to DMARDs was not different
255	between the early and maintenance periods. It is crucial to note that the time point of
256	measuring medication adherence is the maintenance period because RA is a chronic disease

257	that requires DMARDs for a long duration. The third is the difference in participant
258	characteristics. Living status and marital status affected adherence [11, 44]. Our study could
259	not adjust the living status and marital status because we could not include more factors
260	based on our sample size. In addition, the age of the participants may have had an effect. In
261	the original MMAS-8 article [21], the mean age was 52 years; however, in our study, the
262	median age was 64 years, which means that the participants in our study were older, and this
263	may have influenced the results. Furthermore, older people may not have revealed the truth.
264	Thus, when referring to drug adherence studies, the method of measuring adherence, whether
265	the target patient is in the disease's early or maintenance phase, and the patient's
0.00	
266	characteristics should be confirmed before adaptation.
266 267	characteristics should be confirmed before adaptation. Our study detected high social desirability, high educational level, and non-full-time work
	L. L
267	Our study detected high social desirability, high educational level, and non-full-time work
267 268	Our study detected high social desirability, high educational level, and non-full-time work as factors affecting MTX adherence. A previous study reporting MTX adherence found that
267 268 269	Our study detected high social desirability, high educational level, and non-full-time work as factors affecting MTX adherence. A previous study reporting MTX adherence found that adherence is associated with age, sex, race, RA disease activity, patient beliefs about the
267 268 269 270	Our study detected high social desirability, high educational level, and non-full-time work as factors affecting MTX adherence. A previous study reporting MTX adherence found that adherence is associated with age, sex, race, RA disease activity, patient beliefs about the medication, disease duration, mental health, and SES [4,7-11,35-37]. The discrepancy

274	account for this bias [19], no studies have examined how MTX adherence survey accounts
275	for social desirability. The results may have differed since we conducted a factor search that
276	included social desirability. Second, racial differences may have led to different outcomes.
277	Our study was based on a Japanese population; however, previous studies were mainly on
278	white people, black people, and Hispanic people. Canon et al. reported that the adherence to
279	MTX was associated with the Caucasian race [4]. Therefore, adherence may be influenced by
280	race. Third, the definition of medication adherence varies between studies. We used MMAS-8
281	in our study. Conversely, previous studies used other methods to assess medication adherence,
282	such as physicians' estimation, different self-reported scales, drug concentration, tablet count
283	electronic monitors, and other questionnaires. A prior study reported that medication
284	adherence differs because the measurement method employed seems to vary [12]. Therefore,
285	we need to practice caution when using research results because the results may differ
286	depending on the method of measuring adherence and the variables incorporated, including
287	social desirability.
288	Our study had three strengths. First, we assessed social desirability, leading to social
289	desirability bias. To our knowledge, no clinical studies adjusting social desirability have
290	investigated the association between MTX adherence and various factors. Second, to our

It is made available under a CC-BY-NC-ND 4.0 International license .

knowledge, this is the first research to examine MTX adherence in an Asian population. Third,

- the response rate to the questionnaires was high (93.4%), thereby strengthening internal
- 293 validity.
- 294 This study has significant implications for the clinician. Our findings may prevent 295 unnecessary DMARDs changes since physicians tend to overestimate patients' medication 296 adherence [45]. They should confirm MTX adherence before switching or adding DMARDS. 297 Accordingly, this provides an opportunity to reduce the healthcare cost and adverse events of 298 medication. 299 However, this study had several limitations. First, in the multivariable analysis, some 300 immeasurable essential factors (such as characteristics of each participant, joint deformities, 301 number of medications, and MTX dosing frequency) that could affect MTX adherence 302 possibly exist. We did not determine patient personality due to the difficulty in quantifying it. 303 In addition, we did not collect radiographs even if they are necessary for determining joint 304 deformity because they are burdensome for patients. However, we adjusted for joint 305 deformity using the mHAQ to reduce its possible influence on the findings. In addition, 306 although the number of MTX doses was collected, it was not possible to incorporate variables 307 due to sample size limitations. Second, the generalizability of our findings is limited. Our

It is made available under a CC-BY-NC-ND 4.0 International license .

308	study setting was primarily university hospitals in Japan; thus, the results of this study cannot
309	be applied to the clinical setting, in small- and medium-sized hospitals, or in settings
310	including other races. Furthermore, the highest dose of MTX in Japan in the study was 8 mg
311	per week. This dose is less than the standard dose of 20 mg worldwide, which limits the
312	indications. Third, we used a self-reported questionnaire of adherence. Hence, the completed
313	questionnaire possibly influenced social desirability. Although we could not adjust this bias
314	completely, social desirability was added as a factor for analysis. Furthermore, MMAS-8 is
315	"self-perceived adherence" and not true drug adherence. Therefore, even a factorial search
316	including social desirability may not reveal the truth. Forth, The Marlowe-Crowne Social
317	Desirability scale may have inadequate validity and reliability [46]. The validity of this scale
318	has not been examined in the target population of RA patients. There are also negative studies
319	on the reliability of the SDS scale. As a future study, we would like to conduct a validity
320	study of this scale in RA patients.
321	Conclusions

Our results demonstrated that sixty percent of the RA patients had moderate adherence to MTX. Moreover, high MTX adherence in RA patients is associated with high social desirability, high educational level, and non-full-time work.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 326 List of Abbreviations
- 327 ADL: Activities of Daily Living
- 328 BMQ: Beliefs about Medicines Questionnaire
- 329 BPI: Brief Pain Inventory
- 330 CES-D: Center for Epidemiological Studies Depression
- 331 DAS28-ESR: Disease Activity Score (28 joint count)-erythrocyte sedimentation rate
- 332 DMARDs: disease-modifying antirheumatic-drugs
- 333 MCS: mental component summary
- 334 mHAQ: modified Health Assessment Questionnaire
- 335 MMAS-8: Morisky Medication Adherence Scale
- 336 MTX: methotrexate
- 337 NRS: Numerical Rating Scale
- 338 PCS: physical component summary
- 339 RA: rheumatoid arthritis
- 340 SDS: Social Desirability Scale
- 341 SF-8: 8-item Short-Form Health Survey

It is made available under a CC-BY-NC-ND 4.0 International license .

342

343 **Declarations**

344 *Ethics approval and consent to participate*

- The ethics committee of Showa University Hospital (approval number 1446) and other each
- institution approved this study, and informed consent was obtained from all participants
- 347 before study enrolment. All study procedures were performed in accordance with the
- 348 Declaration of Helsinki. Patient information was anonymized and de-identified before
- analysis.
- 350 *Consent for publication*
- 351 Not applicable.
- 352 Availability of data and materials
- 353 The dataset analyzed in this paper is available from the corresponding author on reasonable
- 354 request.
- 355
- 356 About MMAS8
- The use of the MMAS diagnostic adherence assessment instrument is protected by US
 copyrighted and trademarked laws. Permission for use is required. A license is available from

It is made available under a CC-BY-NC-ND 4.0 International license .

359 MORISKY MEDICATION ADHERENCE RESEARCH, LLC., Donald E. Morisky, ScD,

- 360 ScM, MSPH, MMAR, LLC, 294 Lindura Ct., Las Vegas, NV 89138; <u>dmorisky@gmail.com</u>.
- 361

362 *Competing interests*

- 363 Donald E. Morisky holds a copyright for the Morisky Medication Adherence Scale-8, is one
- of its authors, and collects fees in exchange for licenses to use the scale in research. This does
- 365 not alter the authors' commitment to objectivity in research or adherence to data sharing
- 366 policies. He was not involved in any data analysis. For the remaining authors, none were
- 367 declared.
- 368 Funding
- 369 The authors have not received funding to conduct this study.

370 Authors' contributions

- Nobuyuki Yajima: Methodology, Project administration, Writing original draft, Writing –
- 372 Review & Editing
- 373 Takashi Kawaguchi: Supervision, Conceptualization, Project Administration, Writing -
- 374 original draft, Writing Review & Editing
- Ryo Takahashi: Data curation, Writing original draft, Writing Review & Editing

It is made available under a CC-BY-NC-ND 4.0 International license .

376	Hiroki Nishiwaki:	Data curation.	Writing -	original draft.	Writing -	Review & Editing
		,			0	

- 377 Youichi Toyoshima: Data curation, Writing original draft, Writing Review & Editing
- 378 Koei O: Data curation, Writing original draft, Writing Review & Editing
- 379 Tsuyoshi Odai: Data curation, Writing original draft, Writing Review & Editing
- 380 Takayuki Kanai: Data curation, Writing original draft, Writing Review & Editing
- 381 Donald E. Morisky: Supervision, Writing original draft, Writing Review & Editing
- 382 Takuhiro Yamaguchi: Formal Analysis, Supervision, Writing original draft, Writing -
- 383 Review & Editing
- 384 Tsuyoshi Kasama: Supervision, Writing original draft, Writing Review & Editing

385 Acknowledgments

- 386 We thank Noboru Murata (Kikuna Memorial Hospital) and Osamu Namiki for critically
- 387 reviewing the manuscript.

388

389 Authors' information

390 Division of Rheumatology, Department of Medicine, Showa University School of

391 Medicine, Tokyo, Japan

392 Nobuyuki Yajima, Ryo Takahashi, Tsuyoshi Kasama

It is made available under a CC-BY-NC-ND 4.0 International license .

393 Department of Healthcare Epidemiology, Kyoto University Graduate School of

- 394 Medicine and Public Health, Kyoto, Japan
- 395 Nobuyuki Yajima
- 396 Center for Innovative Research for Communities and Clinical Excellence, Fukushima
- 397 Medical University, Fukushima, Japan
- 398 Nobuyuki Yajima
- 399 Department of Practical Pharmacy, School of Pharmacy, Tokyo University of Pharmacy
- 400 and Life Sciences, Tokyo, Japan
- 401 Takashi Kawaguchi
- 402 Division of Nephrology, Department of Internal Medicine, Showa University Fujigaoka
- 403 Hospital, Yokohama, Japan
- 404 Hiroki Nishiwaki
- 405 Showa University Research Administration Center, Tokyo, Japan
- 406 Hiroki Nishiwaki
- 407 Department of Orthopedic Surgery, Showa University Toyosu Hospital, Tokyo, Japan
- 408 Yoichi Toyoshima

It is made available under a CC-BY-NC-ND 4.0 International license .

409 Department of Orthopedic Surgery, Showa University Northern Yokohama Hospital,

- 410 Yokohama, Japan
- 411 Koei Oh
- 412 Department of Internal Medicine, Showa University Northern Yokohama Hospital,
- 413 Yokohama, Japan
- 414 Tsuyoshi Odai
- 415 Department of Rheumatology, Yokohama Asahi Central General Hospital, Kanagawa,
- 416 **Japan.**
- 417 Tsuyoshi Odai
- 418 Department of Nephrology, Kanto Rosai Hospital, Kawasaki, Japan
- 419 Takayuki Kanai
- 420 Department of Community Health Sciences, UCLA Fielding School of Public Health
- 421 Donald E. Morisky
- 422 Division of Biostatistics, Tohoku University Graduate School of Medicine, Miyagi,
- 423 **Japan**
- 424 Takuhiro Yamaguchi

426			
427			
428			
429			
430			
431			
432			
433			
434			
435			
436			

It is made available under a CC-BY-NC-ND 4.0 International license .

437 **References**

453

438	1. van der Heijde DM, van Leeuwen MA, van Riel PL, Koster AM, van 't Hof MA, van
439	Rijswijk MH, et al. Biannual radiographic assessments of hands and feet in a three-year
440	prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum.
441	1992;35:26-34.
442	2. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015
443	American College of Rheumatology Guideline for the treatment of rheumatoid arthritis.
444	Arthritis Care Res (Hoboken). 2016;68:1-25.
445	3. Smolen JS, Landewe RBM, Bijlsma JWJ, Burmester GR, Dougados M,
446	Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid
447	arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
448	Ann Rheum Dis. 2020;79:685-99.
449	4. Cannon GW, Mikuls TR, Hayden CL, Ying J, Curtis JR, Reimold AM, et al.
450	Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess
451	methotrexate adherence and disease activity in clinical practice. Arthritis Care Res
452	(Hoboken). 2011;63:1680-90.

5. Contreras-Yanez I, Ponce De Leon S, Cabiedes J, Rull-Gabayet M, Pascual-Ramos V.

454	Inadequate therapy behavior is associated to disease flares in patients with rheumatoid
455	arthritis who have achieved remission with disease-modifying antirheumatic drugs. Am J
456	Med Sci. 2010;340:282-90.
457	6. Brodtkorb E, Samsonsen C, Sund JK, Bråthen G, Helde G, Reimers A. Treatment
458	non-adherence in pseudo-refractory epilepsy. Epilepsy Res. 2016;122:1-6
459	7. De Cuyper E, De Gucht V, Maes S, Van Camp Y, De Clerck LS. Determinants of
460	methotrexate adherence in rheumatoid arthritis patients. Clin Rheumatol. 2016;35:1335-9.
461	8. DiBenedetti DB, Zhou X, Reynolds M, Ogale S, Best JH. Assessing methotrexate
462	adherence in rheumatoid arthritis: a cross-sectional survey. Rheumatol Ther. 2015;2:73-84.
463	9. Salt E, Frazier SK. Adherence to disease-modifying antirheumatic drugs in patients
464	with rheumatoid arthritis: a narrative review of the literature. Orthop Nurs. 2010;29:260-75.
465	10. Scheiman-Elazary A, Duan L, Shourt C, Shourt C, Agrawal H, Ellashof D, et al. The
466	rate of adherence to antiarthritis medications and associated factors among patients with
467	rheumatoid arthritis: a systematic literature review and metaanalysis. J Rheumatol.
468	2016;43:512-23.
469	11. Waimann CA, Marengo MF, de Achaval S, Cox VL, Garcia-Gonzalez A, Reveille JD,
470	et al. Electronic monitoring of oral therapies in ethnically diverse and economically

It is made available under a CC-BY-NC-ND 4.0 International license .

471 disadvantaged patients with rheumatoid arthritis: consequences of low adherence. Arthritis

- 472 Rheum. 2013;65:1421-9.
- 473 12. Hope HF, Bluett J, Barton A, Hyrich KL, Cordingley L, Verstappen SM.
- 474 Psychological factors predict adherence to methotrexate in rheumatoid arthritis; findings
- from a systematic review of rates, predictors and associations with patient-reported and
- 476 clinical outcomes. RMD Open. 2016;2:e000171.
- 477 13. Tracey, Terence J G. A note on socially desirable responding. Journal of counseling
- 478 psychology. 2016;63:224-32.
- 479 14. Copeland K, Checkoway H, McMichael A. and Holbrook R. Bias due to the
- 480 misclassification in the estimation of relative risk. Am J Epidemiology. 1977;105:488–95.
- 481 15. Richman WL, Weisband S, Kiesler S. and Drasgow F. A meta-analytic study of
- 482 social desirability distortion in computer-administered questionnaires, traditional
- 483 questionnaires, and interviews. Journal of Applied Psychology. 1999;84: 754–775
- 484 16. Holtgraves T. Social desirability and self-reports: testing models of socially desirable
- responding. Pers Soc Psychol Bull. 2004;30:161-72.
- 486 17. Hebel S, Kahn-Woods E, Malone-Thomas S, McNeese M, Thornton L,
- 487 Sukhija-Cohen A, et al. Brief report: discrepancies between self-reported adherence and a

488	biomarker	of	adherence	in	real-world	settings.	J	Acquir	Immune	Defic	Syndr.
489	2020;85:45	4-7.									

- 490 18. van der Straten A, Montgomery ET, Hartmann M, Minnis A. Methodological lessons
- 491 from clinical trials and the future of microbicide research. Curr HIV/AIDS Rep.
- 492 **2013;10:89-102**.
- 493 19. Aaltonen KJ, Turunen JH, Sokka T, Puolakka K, Valleala H. A survey on the
- 494 medication adherence to methotrexate among rheumatoid arthritis patients treated with
- self-administered biologic drugs. Clin Exp Rheumatol. 2016;34:694-7.
- 496 20. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010
- 497 rheumatoid arthritis classification criteria: an American College of Rheumatology/European
- 498 League against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569-81.
- 499 21. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication
- adherence measure in an outpatient setting. J Clin Hypertens. (Greenwich) 2008;10:348-54.
- 501 22. Berlowitz DR, Foy CG, Kazis LE, Bolin LP, Conroy MB, Fitzpatrick P, et al. Effect
- of intensive blood-pressure treatment on patient-reported outcomes. N Engl J Med.
 2017;377:733-44.
- 504 23. Bress AP, Bellows BK, King JB, Hess R, Beddhu S, Zhang Z, et al.

It is made available under a CC-BY-NC-ND 4.0 International license .

505 Cost-effectiveness of intensive versus standard blood pressure control. N Engl J Med.

- 506 2017;377:745-55.
- 507 24. Crowne DP, Marlowe D. A new scale of social desirability independent of
- 508 psychopathology. J Consult Psychol. 1960;24:349-54.
- 509 25. Reynolds WM. Development of reliable and valid short forms of the
- 510 Marlowe-Crowne social desirability scale. J Clin Psych. 1982;38:119-25.
- 511 26. Barger, S. D. The Marlowe-Crowne affair: Short forms, psychometric structure, and
- 512 social desirability. Journal of Personality Assessment. 2003;79:286-305.
- 513 27. Nederhof, A. J. Methods of coping with social desirability bias: A review. European
- 514 Journal of Social Psychology. 1985;15:263-280.
- 515 28. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van
- 516 Riel PL. Modified disease activity scores that include twenty-eight-joint counts.
- 517 Development and validation in a prospective longitudinal study of patients with rheumatoid
- 518 arthritis. Arthritis Rheum. 1995;38:44-8.
- 519 29. Radloff LS. The CES-D scale: a self-report depression scale for research in the
- 520 general population. Appl Psychol Meas. 1977;1:385-401.
- 521 30. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in

522	adherence to treatment	in chronic	c physical illness	. J Psychosom Res.	1999;47:555-67.
-----	------------------------	------------	--------------------	--------------------	-----------------

- 523 31. Ware JE, GlaxoSmithKline. How to score and interpret single-item health status
- 524 measures: a manual for users of the of the SF-8 health survey: (with a supplement on the
- 525 SF-8 health survey). Lincoln, RI; QualityMetric, Inc.; Boston, MA: Health Assessment Lab.
- 526 **2001**.
- 527 32. Birrell FN, Hassell AB, Jones PW, Dawes PT. How does the short form 36 health
- 528 questionnaire (SF-36) in rheumatoid arthritis (RA) relate to RA outcome measures and
- 529 SF-36 population values? A cross-sectional study. Clin Rheumatol. 2000;19:195-9.
- 530 33. Iihara N, Suzuki K, Kurosaki Y, Morita S, Hori K. Factorial invariance of a
- 531 questionnaire assessing medication beliefs in Japanese non-adherent groups. Pharm World
- 532 Sci. 2010;32:432-9.
- 533 34. Uki J, Mendoza T, Cleeland CS, Nakamura Y, Takeda F. A brief cancer pain
- assessment tool in Japanese: the utility of the Japanese Brief Pain Inventory--BPI-J. J Pain
- 535 Symptom Manage. 1998;16:364-73.
- 536 35. Lorish CD, Richards B, Brown S. Missed medication doses in rheumatic arthritis
- 537 patients: intentional and unintentional reasons. Arthritis Care Res. 1989;2:3-9.
- 538 36. Brus HL, van de Laar MA, Taal E, Rasker JJ, Wiegman O. Effects of patient

It is made available under a CC-BY-NC-ND 4.0 International license .

- 539 education on compliance with basic treatment regimens and health in recent onset active
- rheumatoid arthritis. Ann Rheum Dis. 1998;57:146-51.
- 541 37. Viller F, Guillemin F, Briancon S, Moum T, Suurmeijer T, van den Heuvel W.
- 542 Compliance with drug therapy in rheumatoid arthritis. A longitudinal European study. Joint
- 543 Bone Spine. 2000;67:178-82.
- 544 38. Cohen, J. A power primer. Psychol Bull. 1992;112:155-9.
- 545 39. van den Bemt BJ, Zwikker HE, van den Ende CH. Medication adherence in patients
- 546 with rheumatoid arthritis: a critical appraisal of the existing literature. Expert Rev Clin
- 547 Immunol. 2012;8:337-51.
- 548 40. Curtis JR, Bykerk VP, Aassi M, Schiff M. Adherence and persistence with
- 549 methotrexate in rheumatoid arthritis: a systematic review. J Rheumatol. 2016;43:1997-2009.
- 550

551 41. Pullar T, Peaker S, Martin MF, Bird HA, Feely MP. The use of a pharmacological

- indicator to investigate compliance in patients with a poor response to antirheumatic therapy.
- 553 Br J Rheumatol. 1988;27:381-4.
- 42. van den Bemt BJ, den Broeder AA, van den Hoogen FH, Benraad B, Hekster YA,
- van Riel PL, et al. Making the rheumatologist aware of patients' non-adherence does not

It is made available under a CC-BY-NC-ND 4.0 International license .

improve medication adherence in patients with rheumatoid arthritis. Scand J Rheumatol.

557 2011;40:192-6.

- 558 43. Park DC, Hertzog C, Leventhal H, Morrell RW, Leventhal E, Birchmore D, et al.
- 559 Medication adherence in rheumatoid arthritis patients: older is wiser. J Am Geriatr Soc.
- 560 1999;47:172-83.
- 561 44. De Cuyper E, De Gucht V, Maes S, Van Camp Y, De Clerck LS. Determinants of
- 562 methotrexate adherence in rheumatoid arthritis patients. Clin Rheumatol. 2016;35:1335-9.
- 563 45. Gossec L, Molto A, Romand X, Puyraimond-Zemmour D, Lavielle M, Beauvais C,
- the second secon
- 565 disease-modifying drugs in chronic inflammatory rheumatic diseases: A process based on
- 566 literature reviews and expert consensus. Joint Bone Spine. 2019;86:13-19
- 567 46. Nurumov K, Hernández-Torrano D, Ait Si Mhamed A, Ospanova U. Measuring
- 568 Social Desirability in Collectivist Countries: A Psychometric Study in a Representative
- 569 Sample From Kazakhstan. Front Psychol. 2022;13:822931.

570

571 Figure Legend

572 **Figure 1.** Patient flow chart

It is made available under a CC-BY-NC-ND 4.0 International license .

573

574 **Tables**

575 Table 1. Patient characteristics by grade of MTX adherence divided by MMAS-8 (n=165)

			MMAS-8		_
	All	Low	Medium	High	- p
	(n=165)	(n=20)	(n=99)	(n=46)	value
	64	58	65	65.5	0.01
Age, median (IQR)	(54–72)	(44–62)	(53–73)	(59–74)	0.01
Female, n (%)	142 (86.1)	18 (90.0)	84 (84.6)	38 (82.6)	0.74
MTX dose (mg/week),	9 (6.10)	10 (0, 10)	0 (6, 10)	10 (0, 10)	0.17
median (IQR)	8 (6–12)	10 (8–12)	8 (6–10)	10 (8–12)	0.17
MTX dosing frequency					
(times/week), median	3 (2–3)	3 (2–3)	2 (2–3)	2 (2–3)	0.54
(IQR)					
Duration of MTX					
treatment	36 (17–75)	32 (16–79)	35 (18-80)	41 (13–74)	0.15
(month), median (IQR)					
Disease duration	53.5	35	47	60.5	0.05
(month), median (IQR)	(22.5–123.5)	(22–120)	(22–111)	(24–158)	0.95
Concomitant medication					
NSAIDS, n (%)	59 (35.8)	5 (25.0)	36 (36.4)	8 (39.1)	0.53
Corticosteroid, n (%)	27 (16.4)	2 (10.0)	17 (17.2)	8 (17.4)	0.71
Biologics, n (%)	48 (29.1)	7 (35.0)	28 (28.3)	13 (28.3)	0.83
DAS28-ESR, median	2.30	2.01	2.32	2.40	0.00
(IQR)	(1.68–3.00)	(1.37–2.23)	(1.68–3.02)	(2.01–3.15)	0.08
	0	0	0	0.13	0.02
mHAQ, median (IQR)	(0-0.13)	(0-0.25)	(0–0)	(0-0.38)	0.02
BMQ necessity-concern	1 (0, 2)	2(0,2)	1 (0, 2)	2 (0, 2)	0.01
differential, median (IQR)	1 (0–3)	2 (0–3)	1 (0–3)	2 (0–3)	0.81
CES-D (total score ≥ 16), n	37 (26.4)	8 (47.1)	21 (8.3)	8 (20.0)	0.10

It is made available under a CC-BY-NC-ND 4.0 International license .

(%)					
BPI (average NRS pain	2 (1-3)	1 (1-4)	1 (1–3)	1 (3–4)	0.13
score), median (IQR)	2 (1-5)	1 (1-4)	1 (1-5)	1 (5-4)	0.15
SDS, median (IQR)	6 (4–7)	4 (3–6)	6 (4–6)	6.5 (5-8)	0.00
SE 9 (DCS) modion (IOD)	48.1	47.4	49.8	45.6	0.04
SF-8 (PCS), median (IQR)	(42.4–52.1)	(45.8–52.1)	(43.5–52.1)	(40.2–50.2)	0.04
SE 9 (MCS) modion (IOD)	50.2	47.7	50.3	50.0	0.26
SF-8 (MCS), median (IQR)	(45.6–54.1)	(43.0–53.2)	(46.3–53.9)	(46.1–55.0)	0.36
Marital status (married), n	05 (57 0)	11 (55 0)	(1)	22(50.0)	0.27
(%)	95 (57.9)	11 (55.0)	61 (62.2)	23 (50.0)	0.37
Educational level (greater					
than or equal to college	36 (21.8)	5 (25.0)	17 (17.2)	14 (30.4)	0.19
level), n (%)					
Employment status	20 (22 0)	12 ((0,0))		4 (0.7)	0.00
(full-time), n (%)	38 (23.0)	12 (60.0)	22 (22.2)	4 (8.7)	0.00
Living status (living alone),	12 (06.4)	7 (25.0)	24 (24 5)	12 (06 7)	0.62
n (%)	43 (26.4)	7 (35.0)	24 (24.5)	12 (26.7)	0.62

577 IQR, interquartile range; DAS28-ESR, Disease Activity Score (28 joint count)- erythrocyte sedimentation

578 rate; mHAQ, modified Health Assessment Questionnaire; BMQ, Beliefs about Medicines Questionnaire;

579 CES-D, Center for Epidemiological Studies Depression; BPI, Brief Pain Inventory; NRS, Numerical

580 Rating Scale; SDS, Social Desirability Scale; SF-8, 8-item Short-Form Health Survey; PCS, physical

581 component summary; MCS, mental component summary; MTX, methotrexate; MMAS-8, Morisky

582 Medication Adherence Scale

583

584 Table 2. Factors associated with MTX adherence using linear regression analysis (n=165)

	Coef.	95% CI	p value
Age	0.02	0.00-0.03	0.03

It is made available under a CC-BY-NC-ND 4.0 International license .

Female	-0.09	-0.58-0.40	0.73
Disease duration	0.00	-0.00-0.00	0.41
RA activity (DAS28-ESR)	0.16	-0.03-0.35	0.09
Depression state (CES-D)	-0.26	-0.69–0.18	0.25
Belief about medicine	0.01	-0.07-0.09	0.86
(BMQ necessity-concern differential)	0.01	-0.07-0.09	0.80
Social desirability (SDS)	0.14	0.05-0.23	0.00
Educational level (more than or equal to	0.36	-0.10-0.82	0.13
college level or not)	0.30	-0.10-0.82	0.15
Employment status	-0.50	-0.950.05	0.03
(full-time work or not)	-0.30	-0.230.03	0.05

585

* Linear regression analysis was used to detect factors associated with MTX adherence

587 * MTX, methotrexate; RA, rheumatoid arthritis; DAS28-ESR, Disease Activity Score (28 joint

588 count)-erythrocyte sedimentation rate; BMQ, Beliefs about Medicines Questionnaire; CES-D, Center for

589 Epidemiological Studies Depression; SDS, Social Desirability Scale; Coef, regression coefficients; CI,

590 confidence interval

